SWOG clinical trial number
CTSU/C90601

A Randomized Double-Blinded, Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients with Advanced Transitional Cell Carcinoma.

Closed
Phase
Abbreviated Title
Advanced TCC, Gemcitabine, Cisplatin +/- Bevacizumab, Ph III
Activated
08/15/2009
Closed
12/02/2014
Participants
CTSU

Research committees

Genitourinary Cancer

Treatment

Cisplatin Gemcitabine hydrochloride Bevacizumab

Eligibility Criteria Expand/Collapse

The Southwest Oncology Group has endorsed this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute.

Please contact the CTSU directly by either phone (1-888-823-5923) or on the CTSU web site (http://www.ctsu.org/) for information and registration procedures.

Publication Information Expand/Collapse

2021

Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance)

J Rosenberg;K Ballman;S Halabi;P Atherton;R Dreicer;C Holmes;W Stadler;E Plimack;T Flaig;R Dreicer;B Teply;J Pincus;S Tagawa;D Vaena;J Misleh;A Shipstone;A Mortazavi;M Morris Journal of Clinical Oncology Aug 1;39(22):2486-2496; May 14;JCO2100286. doi: 10.1200/JCO.21.00286. Online ahead of print

PMid: PMID33989025

2019

CALGB 90601 (Alliance): Randomized, double blind, placebo-controlled phase III trial comparing gemcitabine and cisplatin with bevacizumab or placebo in patients with metastatic urothelial carcinoma

J Rosenberg;K Ballman;S Halabi;C Watt;R Dreicer;T Flaig;M Morris J Clin Oncol 37(suppl; abstr 4503); American Society of Clinical Oncology (5/31-6/4/19, Chicago IL), oral

Other Clinical Trials

SWOG Clinical Trial Number
S2312

A Phase III Study of Cabazitaxel with or without Carboplatin in Patients with metastatic castrate-resistant prostate cancer (mCRPC), Stratified by Aggressive Variant Signature
Research Committee(s)
Genitourinary Cancer
Activated
09/03/2024
Accrual
0%
Open
Phase
SWOG Clinical Trial Number
S2210

S2210, "Targeted Neoadjuvant Treatment for Patients with Localized Prostate Cancer and Germline DNA Repair Deficiency"
Research Committee(s)
Genitourinary Cancer
Activated
08/14/2023
Accrual
7%
Open
Phase
SWOG Clinical Trial Number
S2200

S2200, A Phase II Randomized Trial of Cabozantinib with or Without Atezolizumab in Patients with Advanced Papillary Renal Cell Carcinoma: PAPMET2
Research Committee(s)
Genitourinary Cancer
Activated
09/19/2022
Accrual
14%
Open
Phase